Knight Therapeutics Launches JORNAY PM for ADHD in Canadian Children
Knight Therapeutics Inc. has launched JORNAY PM in Canada, a new medication for treating ADHD in children aged 6-12. The product, an extended-release formulation of methylphenidate, is the first and only evening-dosed methylphenidate product commercially available in Canada for this age group. JORNAY PM is designed to provide a smooth onset of effect at waking and last into the early evening. It consists of microbeads with a delayed-release layer and an extended-release layer for controlled release throughout the day. The medication's efficacy and safety have been demonstrated in two phase 3 clinical trials, with the most frequent adverse events being insomnia, affect lability, headache, decreased appetite, increased diastolic blood pressure, and upper respiratory tract infection. Knight Therapeutics acquired the exclusive rights to distribute JORNAY PM in Canada and Latin America from Ironshore Pharmaceuticals & Development Inc. The Canadian ADHD news market totals approximately $1.25 billion, with methylphenidates representing over $500 million and growing at over 14% CAGR. ADHD is a chronic neurodevelopmental disorder affecting 5-9% of children and 3-5% of adults. JORNAY PM is expected to provide a new treatment option for children with ADHD in Canada. The launch of JORNAY PM in Canada is a significant development in the treatment of ADHD. With its controlled release formulation and demonstrated efficacy, the medication offers a new option for managing ADHD symptoms in children. As the Canadian ADHD news market continues to grow, the introduction of JORNAY PM is expected to have a positive impact on patients and healthcare providers.
